Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Nimer Alkhatib

Assistant Professor

University of Arizona

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States

About

Nimer Alkhatib is an Adjunct Assistant Professor at the University of Arizona, USA. His research focuses on economic evaluations in healthcare, including cost-effectiveness analyses and budget impact assessments for various therapies, particularly in the context of inflammatory bowel disease, cancer treatments, and biosimilars in the Middle Eastern and North African region. Recent publications highlight his work on the economic implications of tobacco use and pharmacological interventions in various health conditions.

Articles (14)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Amal Badawoud

Associate Professor

princess nourah bint abdulrahman university

SAUDI ARABIA

View details

Ivo Abraham

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Nimer Alkhatib

Research Interests

Make your next move.

Explore related searches

About

Articles (14)

The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs

Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective

Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer

Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan

The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region

Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting

Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective

Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients

Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure

Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients

Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs)

Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing

Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing

Collaborators (2)

Amal Badawoud

Ivo Abraham

Make your next move.